Taha Hesham Salah El Din, Badran Hala Mahfouz, Kandil Hossam, Farag Nabil, Oraby Abbas, El Sharkawy Magdy, Shokry Khaled, Fawzy Fouad, Mahrous Hossam, Bahgat Juliette, Samy Mina, Shaker Mirna Mamdouh
Department of Cardiology, Faculty of Medicine, Cairo University, 27 Nafezet Sheem El Shafae St Kasr Al Ainy, Cairo, 11562, Egypt.
Menoufia University, Shebeen El-Kom, Egypt.
Egypt Heart J. 2021 Feb 23;73(1):17. doi: 10.1186/s43044-021-00140-1.
Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events.
Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD.
The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.
大量流行病学调查和随机临床研究已确定血脂异常是动脉粥样硬化性心血管疾病（ASCVD）的主要促成因素。因此，管理血清胆固醇和低密度脂蛋白水平已成为预防心血管事件努力中的核心目标。
不同组织和协会发布了许多指南，以界定患者风险并为管理策略制定重要建议。文中描述了新型降胆固醇药物（非他汀类药物），其使用主要针对新发ASCVD极高风险患者的二级预防。
本指南以简单易用的形式总结了当前的风险评估方法，并概述了血脂管理的最新数据，以提高医生的认识并帮助在日常实践中实施指南。
